Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Growth Metrics

Skinvisible (SKVI) Long-Term Debt Repayments (2016 - 2024)

Skinvisible (SKVI) has disclosed Long-Term Debt Repayments for 10 consecutive years, with $22500.0 as the latest value for Q1 2024.

Quarterly Long-Term Debt Repayments changed N/A to $22500.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $22500.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $22500.0 for FY2024, N/A changed from the prior year.
Long-Term Debt Repayments hit $22500.0 in Q1 2024 for Skinvisible, down from $245000.0 in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $245000.0 in Q4 2021 to a low of -$130000.0 in Q3 2021.